Prostate Cancer

前列腺癌治疗（PC） 摘要：PC的目的是减少前列腺癌负担。筹委会成员调查 前列腺癌的发展和进展，开发新的临床干预措施，以减少前列腺 癌症发病率和死亡率，以及在人群中设计/测试干预措施。总体目标是： 1)开发前列腺癌预防和检测的新方法; 2）发现新的精确度- 用于预防和/或管理晚期疾病的方法。目前的目标是： 目的1：通过评估AR信号传导和串扰确定治疗干预的新节点 目标2：创建和测试AR以外的晚期前列腺癌新治疗策略 目标3：开发和测试前列腺癌风险和检测的新方法 这些目标至关重要，因为艾滋病的发病率和死亡率高得不成比例， 前列腺癌的病人PC由28名基础、人口和临床研究人员组成 他们已经建立了进行跨学科和跨学科研究的强大机制， 在项目期间产生了许多范式转变和实践改变的发现。 PC成员产生了550份出版物，比上一个项目期增加了60.3%。其中，142 (25.8 151项（占20.4%）是方案内的，自上一个供资周期以来增加了98.4%，这是一个例外; 方案间（27.5%）。总体影响力有所提高，12.4%的期刊出现在具有影响因子的期刊上 >10，平均影响因子为5.7。2016年，SKCC也开始跟踪与作者的合作 目前，47.8%的PC计划出版物来自其他NCI指定的癌症中心; 与其他NCI指定中心合作。PC的整体影响力说明了高影响力 发现出现在期刊上，包括Cancer Cell，Cancer Discovery，J. Clin Invest。分子细胞，临床杂志 Oncol和NEJM。 PC成员在获得资金方面非常富有成效。值得注意的是， 自上次CCSG审查以来，计算总成本和直接成本发生了变化，现在需要排除资金 在上次审查中允许的来源。此外，SKCC最后一次审查是在ARRA高峰期间 经费尽管在比较当前的资金总额与上次审查时存在这些障碍，但PC是强大的。 与癌症相关的总资金从570万美元增加到1100万美元（+93.0%），直接成本也 从400万美元增加到850万美元（+113%）。年度同行评审资金也从440万美元（总额） 770万美元（+75.0%），直接成本从290万美元增加到590万美元（+100.0%）。其中，50.6%是同行-- 审查的资金来自NCI，66.2%来自联合联邦癌症专用同行评审 来源（NCI + DOD癌症计划）。

PROSTATE CANCER PROGRAM (PC) ABSTRACT: The purpose of PC is to reduce prostate cancer burden. PC members investigate the basis of prostate cancer development and progression, developing new clinical interventions to reduce prostate cancer incidence and mortality, and designing/testing interventions in populations. Overarching goals are to: 1) Develop new methods for prostate cancer prevention and detection; and 2) Discover new precision- based approaches for preventing and/or managing advanced stage disease. Current aims are: Aim 1: Identify new nodes of therapeutic intervention via assessment of AR signaling and crosstalk Aim 2: Create and test novel treatment strategies beyond AR for advanced prostate cancer Aim 3: Develop and test new approaches for prostate cancer risk and detection These goals are of critical importance, given the disproportionately high incidence of and mortality from prostate cancer in our catchment area. PC is comprised of 28 basic, population, and clinical researchers who have developed robust mechanisms for conducting interdisciplinary and transdisciplinary research, and have generated a number of paradigm-shifting and practice-changing discoveries in the project period. PC members generated 550 publications, an increase of +60.3% over the prior project period. Of these, 142 (25.8%) were intra-programmatic, an exceptional increase since the last funding cycle of +98.4%; 151 were inter-programmatic (27.5%). Overall impact improved with 12.4% appearing in journals with an impact factor >10 and an average impact factor of 5.7. In 2016, SKCC also began to track collaborations with authors from other NCI-designated Cancer Centers; at present, 47.8% of PC Program publications were in collaboration with other NCI-designated Centers. The overall impact of PC is illustrated high-impact discoveries appearing in journals including Cancer Cell, Cancer Discovery, J. Clin Invest. Mol Cell, J Clin Oncol, and NEJM. PC members have been exceptionally productive in securing funding. Notably, the mechanism for calculating total and direct costs changed since the last CCSG review, now requiring exclusion of funding sources that were allowable in the last review. Further, SKCC was last reviewed during the peak of ARRA funding. Despite these barriers in comparing current funding totals versus the last review, PC is strong. Total cancer relevant funding increased from $5.7M to $11.0M total costs (+93.0%) with direct costs also increasing from $4.0M to $8.5M (+113%). Annual peer-reviewed funding also increased from $4.4M (total) to $7.7M (+75.0%), with direct costs increasing from $2.9M to $5.9M (+100.0%). Of this, 50.6% is peer- reviewed funding derived from NCI, and 66.2% from combined federal cancer-dedicated peer review sources (NCI + DOD Cancer Programs).